looking forward to this update on #SABCS21 with @UCSFCancer docs who have taken care of me throughout my breast cancer rollercoaster, from early stage in 2008 to MBC now. #bcsm
I hope to look at #SABCS21 posters and tweet about them over the next few days. Looks like I'll be snowed in starting Sunday night or Monday, so it'll be a nice break from moving snow.
Our hope lies in #research. Thank you to all the people who study MBC, helping to keep us #NotDeadYet longer. #SABCS21
and CDK 4/6 inhibitors are not the only CDKs that may be important. Samuraciclib is a CDK 7 inhibitor that looks good, at least in those who haven't used fulvestrant before. #SABCS21
Nearest and dearest to me is ER+ MBC. Oral SERDs and SERCAs hold promise in combating endocrine and/or CDK 4/6 resistance, and there are LOTS of trials in this space (although not all are open to those of us with prior fulvestrant) #SABCS21
For #metastatic TNBC immunotherapy (CIT = cancer immunotherapy, like pembrolizumab), especially in PDL1+ tumors, new ADCs (like datopotamab dxd) maybe in combo with CIT, or targeting the androgen receptor look promising. And our friend TDxd makes an apperance here too. #SABCS21
Wrapping up with the #SABCS21 "Year in Review" on MBC, presented by Dr Peter Schmid. First up: HER2+ MBC. TDxd was the big story of 2020/early 2021 - it's moved to recommended 2nd line therapy and might even become 1st line. ADC SYD985 and TKI pyrotinib are ones to keep👀 too.
Watching the @abreastcancer session with an incredible panel including @Maimah @jamilkali @PinkLegacy5050 and Dr. Andrea Phillips. We have to face biases - racism - head on. We can all learn so much from @chrysalisinit and @tigerlilycares. #SABCS21
This is a phase 1 dose escalation trial in heavily pretreated population. What is so promising is that ARV-471 showed efficacy in people who had had progression on a prior SERD, including some who had used oral SERDs in other trials!!!! Watch this one #sabcs21
Next, PROTAC ARV-471, an oral medication. PROTACs are like smart bombs and are super cool, and Dr Parson's slide is an excellent explanation of how they work. #SABCS21
Giredestrant, an oral SERD, shows promise both as monotherapy and in combo with palbociclib. What's impressive about the monotherapy arm is that a lot of the heroes in the trial had progression on prior CDK4/6 inhibitors and a fair number had prior fulvestrant. #SABCS21
Dr Heather Parsons of @DanaFarber presents on the future for ER+ disease, and includes a fantastatic chart of agents in trials (definitely save that chart!). Only crticism: Dr Parsons needs to get on twitter! #SABCS21
Another triplet presented was CDK4/6 inhibitor ribociclib + mTOR inhibitor everolimus + AI exemestane. Triplet was NOT compared to everolimus + exemestane (with have been used for years) so we don't know if adding ribo adds any benefit. Infections were 😳 #SABCS21
must note an additional downside: gedatolisib is an intravenous medication, so it ties one to an in-person visit 3/4 weeks (assuming that is the dosing that moves forward). #SABCS21
This is the way I #SABCS21
Overall response rates were good, although better in Cohort D (3 weeks on/1 week off) vs C (weekly gedatolisib). This was a Phase 1b and I think this is a drug worth keeping an eye on. #sabcs21 #bcsm
no surprises that with 3 drugs side effects were significant, although as @MOliveira_MD notes prophylactic treatment may mitigate some of these side effects. #SABCS21
Gedatolisib is a PI3K/mTOR inhibitor, used in combo with CDK4/6 inhibitor palbociclib and endocrine therapy (letrozole or fulvestrant). Cohorts C & D used fulvestrant and were heavily pretreated, with the difference between the 2 arms being how gedatolisib was dosed. #SABCS21
Do the results from BYLieve cohort 3, a heavily pretreated group, showing that PFS is associated with the fraction of ctDNA lend more support to following ctDNA over the course of treatment? If there isn't a ⬇️in ctDNA should tx be changed? @hoperugo? #SABCS21
It was dark and frigid when my alarm went off at 4:45 this AM, so I pulled the covers back over my head &went back to sleep. Will watch the recordings of this AM’s spotlight sessions now, when the heat is on and it’s a sunny, balmy 13° outside. Virtual has its benefits. #sabcs21
It’s time to step away from the #SABCS21 computer and pick up the snow shovel - thankfully as sessions are recorded can catch up later! #OneBenefitOfAVirtualMeeting
getting a shout out from Dr. @tmprowell at the @abreastcancer FDA-#advocate "lunch" for my being vocal about the need for decentralized clinical trials and how it has influenced the @FDAOncology is making me 🥲 and motivating me to keep being an #advocate #SABCS21
super interesting potential future option for those who have progression on CDK 4/6 inhibitors: samuraciclib, a CDK 7 inhibitor, for those who do NOT have mutant TP53. The AEs described were before they routinely started giving nausea and diarrhea prophylaxis. #SABCS21
dude behind Dr Matthew Ellis: mask below your nose does jack squat 🙄 You'd think after 20 months adults would know how to #MaskUp properly. #SABCS21
love seeing how data from the @MBC_Project is being used in other research! #SABCS21 #SpitForScience #DroolForData @Nikhilwagle @corrie_painter
The concept of routine monitoring for ESR1 mutations in PADA1 is intriquing, but there are quesitons to be answered and we really need to see if there is a difference in OS if emerging resistance to AIs is found sooner. #SABCS21
with ribociclib/letrozole absolute ctDNA level at baseline was prognositic. We really should be gathering this type of data in all people with MBC! #biomarkers #SABCS21
Interesting concept with PADA1 - regular monitoring to look for ESR1 mutation & changing therapy from AI to fulv instead of waiting for overt progression (by imaging or symptoms) doubled PFS. The real test will be seeing if there is an OS benefit to earlier switch. #SABCS21 #bcsm
.@SABCSSanAntonio looks like posters are now listed in numeric order - thank you!!! #SABCS21